Satellite Symposia and Product Theaters

THSNA is happy to present the 2022 Satellite Symposium Program. Please note the following:

  • Each event is planned independently of the THSNA program committee and THSNA does not endorse the programming content.
  • You must be a THSNA registrant in order to attend any satellite symposia.
  • There is no cost to attend these symposia.
  • All symposia occur during a meal and food will be provided.
  • If a pre-registration link is not provided, all admittance will be on a first-come, first-served basis.
  • Any pre-registrants not present at the session room door 10 minutes prior to the start of the program will be removed from the pre-registrant list.

Tuesday, August 16 - Breakfast

Are Higher Factor Levels a Rising Consideration when Selecting a Hemophilia Treatment?

Sponsored By: Novo Nordisk, Inc.

7:15 - 8:15 AM, Chicago Ballroom 6
This program will discuss the clinical relevance of reaching high factor activity levels in patients with hemophilia. An increased risk of bleeding episodes exists with time spent at low factor activity levels, and the World Federation of Hemophilia recognizes the importance of high factor activity levels and maintaining hemostasis in patients with hemophilia. The pharmacokinetic and clinical characteristics of products used to treat patients with hemophilia will also be presented.
Click Here to take in our post event survey.


New Clinical Data for Prophylaxis in von Willebrand Disease and Hemophilia A

Sponsored By: Octapharma AG

7:15 - 8:15 AM, Chicago Ballroom 9 & 10
Join Jill Johnsen, Robert Sidonio and Craig Kessler for this symposium putting prophylaxis under the spotlight and presenting new clinical data and ongoing investigations for its use in people with von Willebrand disease (VWD) and hemophilia A. The potential for prophylaxis to offer optimal bleed protection in people with VWD will be discussed, supported by new clinical data from a recently completed prospective trial of prophylaxis with a von Willebrand factor/coagulation factor VIII (VWF/FVIII) concentrate. Next generation sequencing (NGS) is a powerful tool whose use to characterize VWF mutations may improve VWD diagnosis and management. In people with severe hemophilia A, prophylaxis is widely accepted as the standard of care, and should be personalized to the patient’s needs. However, the lack of head-to-head studies of different FVIII products makes it challenging to make informed treatment decisions. Insights into the relative effects of different products can be obtained through indirect comparisons using validated statistical methodology. The results of such a comparison of personalized prophylaxis studies in hemophilia A will be presented and discussed. The differential binding capacity for rFVIII concentrates could have implications in platelet biology and new scientific data will be presented.

Tuesday, August 16 - Lunch

Long-term Monitoring of Clinical Efficacy and Safety Parameters for Investigational Hemophilia Gene Therapy

Sponsored By: Pfizer

12:00 - 1:00 PM, Chicago Ballroom 6
This symposium will discuss the importance of patient monitoring both in the short- and long-term, exploring the variables that need to be considered in order to assess clinical efficacy and safety parameters of gene therapy.
Presenters of this symposium will explore the practicalities of monitoring these parameters, focusing on coagulation assays and liver investigations, and review the questions that need to be addressed in the future in order to further our understanding of the mechanisms underlying this potential therapeutic approach. Gene therapy for the treatment of hemophilia is investigational. There are no gene therapies currently approved in the US for hemophilia.


Help Crack the Case! A Hemophilia A Mystery Game and Afternoon of Discussion

Sponsored By: Genentech

12:00 - 1:00 PM, Chicago Ballroom 9 & 10
The right patient for a different type of hemophilia A treatment may not be who you think it is. That's why Genentech invites you to Help Crack the Case!— in a fun-filled interactive mystery game show—at this year's THSNA symposium. You'll hear from real patients and caregivers to find out just who's right for a subcutaneous prophylaxis option, and play along with our expert contestant, Dr. Michael Silvey.

Throughout our game show, we’ll explore considerations for identifying potential patients and learn more about the different patient types. You may be surprised at who these ‘typical’ patients turn out to be! Plus, you’ll have an opportunity to have your questions answered in our live Q&A session. We look forward to seeing you there!


Tuesday, August 16 - Dinner

The First and Only FDA-approved Agent for Reversal of FXa Inhibitor Activity in Patients with Life-threatening or Uncontrolled Bleeding

Sponsored By: AstraZeneca

6:00 - 7:00 PM, Chicago Ballroom 6
This program will discuss the burden of life-threatening bleeds related to FXa inhibitors, and focus on the mechanism of action, efficacy, and safety of a reversal agent indicated for patients treated with anticoagulants who have life-threatening bleeding.
Continuing education credits will not be offered for this program.


2022 Dinner Symposium: Advancing New Frontiers in Hemophilia Management

Sponsored By: BioMarin Pharmaceutical Inc.

6:00 - 7:00 PM, Chicago Ballroom 9 & 10
Recognizing the history and reasoning for exploring gene therapy in lifelong conditions like hemophilia will be a focus of this conversation with the experts. During this dinner symposium, attendees will be part of expert discussions on topics relating to liver health in the context of liver-directed gene therapy, follow-up care and surveillance registries in patients with hemophilia, and practical logistics for establishing and maintaining successful gene therapy transfer clinic operations. The four leading experts will provide updates on these cutting-edge, scientific topics followed by an open panel discussion with attendees. We hope that you will join us. To pre-register for this satellite symposium, click here.
Continuing education credits will not be offered for this program.


Wednesday, August 17 - Breakfast

Introduction to a Treatment for Adults with Acute Hepatic Porphyria, including Acute Intermittent Porphyria

Hosted by Alnylam Pharmaceuticals

7:00 - 8:00 AM, Chicago Ballroom 6
Presenter: Ilene C. Weitz, MD
Professor of Clinical Medicine, Jane Anne Nohl Division of Hematology
University of Southern California

Join Alnylam Pharmaceuticals for a presentation on a treatment for adults with acute hepatic porphyria (AHP) – including acute intermittent porphyria (AIP). AHP is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks. The cardinal symptom of an AHP attack is severe, diffuse abdominal pain.

This presentation is intended for US Healthcare Professionals only and a range of topics will be discussed, including:
• AHP disease overview and pathophysiology
• Introduction to AHP treatment
• Mechanism of Action
• Efficacy and safety results from the Phase 3 Study and open-label extension
Please join Alnylam Pharmaceuticals and Dr. Ilene Weitz to learn more about this treatment for adults with acute hepatic porphyria (AHP).


Novel Investigational Approaches for Hemophilia Management

Sponsored By: Sanofi

7:00 - 8:00 AM, Chicago Ballroom 9 & 10
The symposium Novel Investigational Approaches for Hemophilia Management, organized by Sanofi, is intended for clinical and research experts in thrombosis, hemostasis, and vascular biology. Given the rapidly evolving therapeutic landscape in hemophilia management, there is a need for education on emerging treatments with novel mechanisms of action (MOA) and mechanisms of extension (MOE). The symposium will be presented in three parts:

Part 1 will provide a brief overview of current hemophilia management and unmet needs
Part 2 will describe the investigational molecule efanesoctocog alfa, with an MOE that overcomes the VWF-imposed half-life ceiling for FVIII replacement, and an overview of its clinical trial program
Part 3 will present the MOA of the investigational siRNA molecule fitusiran, and will conclude with an overview of its clinical trial program

Continuing education credits will not be offered for this program.


Wednesday, August 17 - Lunch

Prophylaxis in Patients with von Willebrand Disease: Expert Perspectives and Shared Experiences

This event is organized and accredited by MediCom Worldwide, Inc. This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

12:35 - 1:35 PM, Chicago Ballroom 6
Lunch will be served. We invite you to join us for a dynamic and interactive panel discussion focused on new advances in prophylaxis treatment for von Willebrand Disease (VWD) and data supporting emerging therapeutic strategies. Our panel will spend time addressing guidelines, treatment strategies, and patient management considerations. Come prepared with your questions for an engaging discussion.
Click Here to take part in the post survey.

Robert Sidonio, Jr., MDChair
Associate Director, Hemostasis and Thrombosis
Emory University - Atlanta, Georgia

Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Director, Clinical Research Center
McGovern Medical School, The University of Texas Health Science Center - Houston, Texas

Angela C. Weyand, MD
Clinical Assistant Professor, Pediatrics - Hematology/Oncology
University of Michigan - Ann Arbor, Michigan

CME Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 22-005-154


Gene Therapy Eligibility: Delineating Differences from Clinical Trial to Clinical Practice

Sponsored By: CSL Behring Medical Affairs

12:35 - 1:35 PM, Chicago Ballroom 9 & 10
Join us and engage in a robust dialogue covering clinical and psychosocial considerations for gene therapy. This panel discussion, led by speakers from multidisciplinary teams will address topics such as:

1) Determining patient eligibility, insights from clinical trial to apply to clinical practice
2) Addressing liver health considerations and evaluation for referrals to a partnering hepatologist
3) Assessing eligibility based on lifestyle screening, patient expectations and commitment of therapy

Michael Recht, MD, PhD, MBA
Chief Science Officer, American Thrombosis and Hemostasis Network - Rochester, New York
Professor of Clinical Pediatrics, Yale University School of Medicine - New Haven, Connecticut

Sabrina Farina, LMSW
Senior Social Worker
Gulf States Hemophilia and Thrombophilia Treatment Center
UT Health Houston - Houston, Texas

Mark Reding, MD
Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center - Minneapolis, Minnesota

Bruce Luxon, MD, PhD
Chair of the Department of Medicine
Chief of Service for the Department of Medicine at Georgetown University Hospital - Washington, DC
* Dr Luxon’s clinical focus is in hepatology, with special expertise in autoimmune hepatitis and cholestatic liver diseases as well as hepatitis C

Continuing education credits will not be offered for this program

Wednesday, August 17 - Dinner

Immune Thrombocytopenia: Expert Guidance to Integrate Emerging Therapies into Clinical Practice

Sponsored By: Clinical Care Options, LLC

6:20 - 7:20 PM, Chicago Ballroom 6
This 1.0-hour, CME-certified live satellite symposium will feature expert faculty presentations and discussions on integrating established and emerging therapies into the clinical management of immune thrombocytopenia (ITP). Topics that will be discussed will include treatment considerations for patients who are newly diagnosed with ITP, strategies for the optimal selection and sequencing of therapies for patients with progressing ITP, and the integration of novel and emerging therapies into the treatment of ITP. The faculty presentations and discussions also will feature expert guidance on the application of current clinical algorithms and evidence-based guidelines to the management of steroid-unresponsive ITP and considerations for treating ITP in special patient populations, such as children and those with chronic liver disease. These presentations will highlight key abstracts presented at THSNA 2022. Of importance, the faculty presenters will have the opportunity to engage in a lively panel discussion while answering pressing questions from the audience.

Continuing education of 1.00 AMA Credit will be offered for this program.


Focus on Factor

Sponsored By: Sanofi

6:20 - 7:20 PM, Chicago Ballroom 9 & 10
Treating hemophilia is often about balancing clinical needs with the lifestyle of each patient. Please join our upcoming symposium, Focus on Factor, at this year’s Thrombosis & Hemostasis Summit of North America (THSNA). During this time, Joanna Davis, MD and Guy Young, MD will share clinical data on treatment options of hemophilia A and hemophilia B. Q&A will follow the presentation.

Continuing education credits will not be offered for this program


Thursday, August 18 - Breakfast

Emerging Strategies in Hemophilia: Restoring the Hemostatic Balance

Sponsored By: Clinical Care Options, LLC

6:45 - 7:45 AM, Chicago Ballroom 6
The 1.0-hour, CME-certified satellite symposium will include an engaging discussion on the management of hemophilia A and B. Expert faculty will use case discussions to highlight the challenges with factor VIII and factor IX replacement, the health burden of hemophilia care, and the need for more novel treatments. In addition, faculty will cover the future of hemophilia therapy, which includes novel therapies aimed at restoring hemostatic balance by blocking/targeting the tissue factor pathway inhibitor or antithrombin. The symposium will close with a panel discussion of key abstracts on hemophilia management from THSNA 2022 and an audience question and answer session.

Continuing education of 1.00 AMA Credit will be offered for this program.


Raising the Bar for People with Hemophilia and Inhibitors: Clinician and Patient Perspectives on Acute Bleed Management with Eptacog Beta

Sponsored By: HEMA Biologics

6:45 - 7:45 AM, Chicago Ballroom 9 & 10
Inhibitor development remains the most serious complication of hemophilia A or B treatment, causing significant burden on the patient, their family, providers, and the healthcare system.

Abundant prophylaxis and bleed treatment options exist for hemophilia patients without inhibitors, bringing health equity within reach. For patients with inhibitors, however, acute bleed management has lagged. Even for those on prophylaxis with non-replacement therapies, spontaneous and traumatic bleeding events are still a reality. Having different options for both prophylaxis and bleed control empowers clinicians to individualize and tailor treatment regimens, providing patients with opportunities to improve their clinical outcomes and pursue their life goals. The objectives of therapy are enabling individuals with inhibitors to participate in their life in the manner that they choose, and not be limited by their disease or by the treatment of their disease.

Join a panel of experts, including an individual with hemophilia A and inhibitors, to discuss their clinical experience with eptacog beta and its contribution towards achieving health equity in patients with hemophilia A or B with inhibitors.

The discussion will be moderated by Leonard A. Valentino, MD, and feature a subject matter expert who has thrived despite inhibitors, and Robert Sidonio Jr., MD.

Continuing Education credit will not be offered.